Cargando…

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

Multiple myeloma (MM) is a heterogeneous plasma cell malignancy and remains incurable. B-cell lymphoma-2 (BCL2) protein correlates with the survival and the drug resistance of myeloma cells. BH3 mimetics have been developed to disrupt the binding between BCL2 and its pro-apoptotic BCL2 family partne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Jiusheng, Park, Dongkyoo, Wang, Mengchang, Nooka, Ajay, Deng, Qiaoya, Matulis, Shannon, Kaufman, Jonathan, Lonial, Sagar, Boise, Lawrence H., Galipeau, Jacques, Deng, Xingming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053685/ https://www.ncbi.nlm.nih.gov/pubmed/27049723 http://dx.doi.org/10.18632/oncotarget.8513

Ejemplares similares

BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models
por: Vervloessem, Tamara, et al.
Publicado: (2020)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth
por: Wang, Mengchang, et al.
Publicado: (2014)

The BDA; together
por: Woodrow, Martin
Publicado: (2020)

BDA AGMs
Publicado: (2023)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Bcl2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation
por: Xie, Maohua, et al.
Publicado: (2015)

Targeting DNA Replication Stress for Cancer Therapy
por: Zhang, Jun, et al.
Publicado: (2016)

Maltose-Binding Protein Fusion Allows for High Level Bacterial Expression and Purification of Bioactive Mammalian Cytokine Derivatives
por: Pennati, Andrea, et al.
Publicado: (2014)

Targeting Bcl2 in cancer
por: Chen, Guo, et al.
Publicado: (2015)

A MCP1 fusokine with CCR2-specific tumoricidal activity
por: Rafei, Moutih, et al.
Publicado: (2011)

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy
por: Nougarède, Adrien, et al.
Publicado: (2018)

The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist
por: Rautureau, G J P, et al.
Publicado: (2012)

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Kanakaveti, Vishnupriya, et al.
Publicado: (2022)

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
por: Gupta, Vikas A, et al.
Publicado: (2021)

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
por: Bajpai, Richa, et al.
Publicado: (2020)

The BDA guide to successful brickwork /
Publicado: (2005)

BDA commits to tackling racism
Publicado: (2020)

366 soles.
Publicado: (1980)

TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization
por: Li, Yixiang, et al.
Publicado: (2020)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Eddie Crouch is new BDA Chair
Publicado: (2020)

Mutual Regulation of Bcl-2 Proteins Independent of the BH3 Domain as Shown by the BH3-Lacking Protein Bcl-x(AK)
por: Plötz, Michael, et al.
Publicado: (2012)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Idomeneo KV 366
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1979)

Antagonizing Bcl-2′s BH4 domain in cancer
por: Vervloessem, Tamara, et al.
Publicado: (2015)

Bcl2 inhibition of mitochondrial DNA repair
por: Xie, Maohua, et al.
Publicado: (2015)

Bcl2 Family Functions as Signaling Target in Nicotine-/NNK-Induced Survival of Human Lung Cancer Cells
por: Deng, Xingming
Publicado: (2014)

BH3 Response Profiles From Neuroblastoma Mitochondria Predict Activity of Small Molecule Bcl-2 Family Antagonists
por: Goldsmith, Kelly C., et al.
Publicado: (2009)

Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients
por: Habib, Jakob, et al.
Publicado: (2015)

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia
por: Gaudette, Brian T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qpf2rvbsd9v20q8vvrqj4lr9jn